274
Participants
Start Date
October 16, 2018
Primary Completion Date
August 27, 2020
Study Completion Date
January 18, 2024
BMS-986213
Relatlimab + Nivolumab specified dose on specified days
Nivolumab
Specified dose on specified days
XELOX
Oxaliplatin + capecitabine
FOLFOX
Oxaliplatin + leucovorin + fluorouracil
SOX
Oxaliplatin + tegafur/gimeracil/oteracil potassium
Local Institution - 0002, Rancagua
Local Institution - 0079, Santiago
Local Institution - 0089, Vienna
Local Institution - 0091, Brussels
Local Institution - 0010, Ciudad Autónoma de Buenos Aires
Local Institution - 0078, CABA
Local Institution - 0027, Westmead
Local Institution - 0092, Leuven
Local Institution - 0003, Heidelberg
Local Institution - 0029, Malvern
Local Institution - 0008, Shepparton
Local Institution - 0007, Herston
Local Institution - 0088, Bergen
Local Institution - 0028, Bedford Park
Local Institution - 0005, Murdoch
Local Institution - 0087, Trondheim
Local Institution - 0090, Graz
Local Institution - 0020, Milan
IRCCS Istituto Nazionale Tumori Milano, Milan
Local Institution - 0018, Hamburg
Local Institution - 0045, Dijon
Virginia Cancer Institute, Richmond
Local Institution - 0073, Besançon
Local Institution - 0057, Madrid
Local Institution - 0058, Madrid
Local Institution - 0012, Hanover
Local Institution - 0071, Montpellier
Local Institution - 0016, Marburg
Local Institution - 0017, Essen
Local Institution - 0081, Essen
Local Institution - 0059, Bilbao
Local Institution - 0060, Zaragoza
Local Institution - 0083, Cologne
Local Institution - 0014, Frankfurt
Local Institution - 0015, Mannheim
Local Institution - 0013, Heidelberg
Local Institution - 0043, Paris
Local Institution - 0072, Paris
Local Institution - 0054, Dallas
Local Institution - 0046, Rouen
Local Institution - 0056, Aurora
Local Institution - 0047, Avignon
Local Institution - 0040, Los Angeles
Local Institution - 0077, Santa Monica
Scripps Clinic, La Jolla
Hoag Memorial Hospital Presbyterian, Newport Beach
Local Institution - 0041, Orange
Local Institution - 0049, Clovis
Local Institution - 0052, Seattle
Local Institution - 0038, Singapore
Local Institution - 0001, Viña del Mar
Local Institution - 0064, Duarte
Local Institution - 0062, New Haven
Local Institution - 0050, Hackensack
Local Institution - 0009, Buenos Aires
Local Institution - 0011, San Miguel de Tucumán
Local Institution - 0024, Kelowna
Local Institution - 0063, Halifax
Local Institution - 0070, Toronto
Local Institution - 0095, Québec
Local Institution - 0055, Trois-Rivières
Local Institution - 0080, Santiago
Local Institution - 0031, Brno
Local Institution - 0030, Olomouc
Local Institution - 0082, Dresden
Local Institution - 0021, Roma
Local Institution - 0086, Oslo
Local Institution - 0093, Warsaw
Local Institution - 0067, San Juan
Local Institution - 0099, Badajoz
Local Institution - 0098, Barcelona
Local Institution - 0061, Barcelona
Local Institution - 0075, Manchester
Local Institution - 0035, Nottingham
Local Institution - 0032, Coventry
Local Institution - 0036, Lancaster
Local Institution - 0034, London
Local Institution - 0069, Northwood
Local Institution - 0033, Southampton
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY